Skip to main content
GERON CORP logo

GERON CORP — Investor Relations & Filings

Ticker · GERN ISIN · US3741631036 LEI · 549300T282D7Z2YESL90 US Manufacturing
Filings indexed 1,017 across all filing types
Latest filing 2026-04-07 Annual Report
Country US United States of America
Listing US GERN

About GERON CORP

https://www.geron.com/

Geron Corp is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies. Its lead product, imetelstat, is a first-in-class telomerase inhibitor approved for the treatment of certain blood cancers. The company's scientific approach targets telomerase to alter the course of hematologic myeloid malignancies, with the goal of extending and enhancing the lives of patients.

Recent filings

Filing Released Lang Actions
ARS - GERON CORP (0000886744) (Filer)
Annual Report
2026-04-07 English
DEF 14A - GERON CORP (0000886744) (Filer)
Proxy Solicitation & Information Statement
2026-04-07 English
SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - GERON CORP (0000886744) (Issuer)
Director's Dealing
2026-03-26 English
3 - GERON CORP (0000886744) (Issuer)
Director's Dealing
2026-03-26 English
4 - GERON CORP (0000886744) (Issuer)
Director's Dealing
2026-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.